{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:18:19Z","timestamp":1793351899165,"version":"4.5.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["HASKET24B0"],"award-info":[{"award-number":["HASKET24B0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["IRB 24\\u2013022766"],"award-info":[{"award-number":["IRB 24\\u2013022766"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jcf.2025.07.013","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T20:26:29Z","timestamp":1753388789000},"page":"1090-1093","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Elevated serum lipase in infants with cystic fibrosis exposed to prenatal and postnatal elexacaftor\/tezacaftor\/ivacaftor"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3198-7966","authenticated-orcid":false,"given":"Haley","family":"Haskett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4171-3827","authenticated-orcid":false,"given":"Christopher","family":"Fortner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Shanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4431-0644","authenticated-orcid":false,"given":"Clement L","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10408","key":"10.1016\/j.jcf.2025.07.013_bib0001","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","article-title":"CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis","volume":"402","author":"Taylor-Cousar","year":"2023","journal-title":"Lancet"},{"issue":"10212","key":"10.1016\/j.jcf.2025.07.013_bib0002","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jcf.2025.07.013_bib0003","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s10995-016-2181-z","article-title":"Attitudes and decision making related to pregnancy among young women with cystic Fibrosis","volume":"21","author":"Kazmerski","year":"2017","journal-title":"Matern Child Health J"},{"key":"10.1016\/j.jcf.2025.07.013_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.914790","article-title":"The exocrine pancreas in cystic fibrosis in the era of CFTR modulation: a mini review","volume":"10","author":"McKay","year":"2022","journal-title":"Front Pediatr"},{"issue":"2","key":"10.1016\/j.jcf.2025.07.013_bib0005","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000530261","article-title":"Prenatal Cystic Fibrosis transmembrane conductance regulator modulator therapy: a promising way to change the impact of Cystic fibrosis","volume":"50","author":"Gomez-Montes","year":"2023","journal-title":"Fetal Diagn Ther"},{"issue":"5","key":"10.1016\/j.jcf.2025.07.013_bib0006","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcf.2021.03.018","article-title":"Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy","volume":"20","author":"Fortner","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2025.07.013_bib0007","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jcf.2022.04.005","article-title":"A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.07.013_bib0008","article-title":"Outcomes of prenatal use of elexacaftor\/tezacaftor\/ivacaftor in carrier mothers to treat meconium ileus in fetuses with cystic fibrosis","volume":"6","author":"Metcalf","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2025.07.013_bib0009","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jcf.2021.12.004","article-title":"Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor","volume":"21","author":"Collins","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2025.07.013_bib0010","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jcf.2024.06.003","article-title":"Clinical outcomes of two infants with cystic fibrosis, including presence of the vas deferens, born to a woman with cystic fibrosis taking CFTR modulators during both pregnancies","volume":"23","author":"Kowalik","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2025.07.013_bib0011","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1164\/rccm.202008-3177OC","article-title":"Ivacaftor in infants aged 4 to <12 months with cystic fibrosis and a gating mutation. Results of a two-part phase 3 clinical trial","volume":"203","author":"Davies","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"15","key":"10.1016\/j.jcf.2025.07.013_bib0012","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1111\/bph.16417","article-title":"Extent of foetal exposure to maternal elexacaftor\/tezacaftor\/ivacaftor during pregnancy","volume":"181","author":"Li","year":"2024","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.jcf.2025.07.013_bib0013","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1517\/14740338.2016.1165666","article-title":"A safety evaluation of ivacaftor for the treatment of cystic fibrosis","volume":"15","author":"McColley","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jcf.2025.07.013_bib0014","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2022-001289","article-title":"Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design","volume":"9","author":"Jain","year":"2022","journal-title":"BMJ Open Resp Res"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325015358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325015358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:36:27Z","timestamp":1779953787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325015358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1569199325015358"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.07.013","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elevated serum lipase in infants with cystic fibrosis exposed to prenatal and postnatal elexacaftor\/tezacaftor\/ivacaftor","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}